Oric Pharmaceuticals, Inc. 8-K

What Happened

• Oric Pharmaceuticals (ORIC) filed a Form 8-K dated February 23, 2026 reporting activity under its existing “at-the-market” (ATM) sales agreement with Jefferies LLC. As of February 23, 2026 the company had sold 13,478,432 shares for gross proceeds of approximately $139.7 million (before commissions and expenses) under the March 11, 2024 prospectus supplement.
• On February 26, 2026 Oric filed a new prospectus supplement (the 2026 Prospectus Supplement) with the SEC to offer and sell up to $200.0 million of common stock under the same Sales Agreement. No further sales will be made under the 2024 prospectus supplement. The company also filed a legal opinion related to the 2026 Prospectus Supplement (Exhibit 5.1).

Key Details

• 13,478,432 shares sold under the ATM program as of Feb 23, 2026.
• Gross proceeds from those sales: ~ $139.7 million (commissions and expenses not yet deducted).
• Sales agent: Jefferies LLC under an Open Market Sale Agreement originally entered May 6, 2021.
• New prospectus supplement filed Feb 26, 2026 to offer up to $200.0 million; 2024 prospectus supplement is closed to further sales.

Why It Matters

• This filing shows Oric has been using an ATM program to raise capital and has already raised a material amount (~$139.7M gross), which can fund operations, programs, or extend its cash runway.
• The new prospectus supplement re-establishes capacity to sell up to $200M of stock through the ATM, meaning additional dilution is possible if shares are sold under the new supplement.
• Investors should note proceeds cited are gross amounts (net proceeds will be lower after sales agent commissions and expenses), and the filing is procedural—no specific use of proceeds or timing of future sales is announced in this 8-K.